Table 1 Alterations of Mdmx, Mdm2 and p53 in 115 primary breast cancers
Characteristics | Patients no. (%) | Mdmx amplification | Mdm2 overexpression | p53 disfunction | |||
|---|---|---|---|---|---|---|---|
no. (%) | P | no. (%) | P | no. (%) | P | ||
Tumor size1 | 36 (31.3%) | 22 (61.1%) | 19 (41.3%) | 8 (22.2%) | |||
d≦20 mm | 66 (57.4%) | 35 (53.0%) | 0.710 | 21 (31.8%) | 0.301 | 29 (47.5%) | 0.009 |
50 mm > =d > 20 mm | 13 (11.3%) | 8 (61.5%) | 4 (30.8%) | 7 (53.8%) | |||
d > 50 mm | |||||||
Grade | |||||||
I | 9 (7.8%) | 7 (77.8%) | 5 (55.6%) | 0.738 | 0 (0) | 0.001 | |
II | 67 (58.3%) | 38 (56.7%) | 0.244 | 22 (32.8%) | 22 (32.8) | ||
III | 39 (33.9%) | 20 (51.3%) | 17 (43.6%) | 22 (56.4%) | |||
Nodal status2 | 0.122 | 0.348 | |||||
N | 51 (44.3%) | 31 (60.8%) | 0.453 | 24 (47.1%) | 18 (35.3%) | ||
N+ | 64 (55.7%) | 34 (53.1%) | 20 (31.2%) | 26 (40.6%) | |||
ER status | 0.116 | 0.016 | |||||
Negative | 42 (36.5%) | 24 (57.1%) | 1.000 | 12 (28.6%) | 22 (52.4%) | ||
Positive | 73 (63.5%) | 41 (56.2%) | 32 (43.8%) | 22 (30.1%) | |||
PR status | 4 | 0.241 | 0.185 | ||||
Negative | 5 (39.1%) | 22 (48.9%) | 0.248 | 14 (31.1%) | 20 (44.4%) | ||
Positive | 70 (60.9%) | 43 (61.4%) | 30 (42.9%) | 24 (34.3%) | |||
HER-2 status | 0.330 | 0.305 | |||||
Negative | 93 (80.9%) | 54 (58.1%) | 0.633 | 38 (40.9%) | 37 (40.7%) | ||
Positive | 22 (19.1%) | 11 (50.0%) | 6 (27.3%) | 7 (31.8%) | |||
Ki67 expression | 1.000 | 0.006 | |||||
Low | 44 (38.3%) | 28 (63.6%) | 0.251 | 17 (38.6%) | 10 (22.7%) | ||
High | 71 (61.7%) | 37 (52.1%) | 27 (38.0%) | 34 (47.9%) | |||
Mdmx amplification | 0.176 | 0.033 | |||||
Yes | 65 (56.5%) | ___ | ___ | 21 | 19 | ||
No | 50 (43.5%) | 23 | 25 | ||||
Mdm2 overexpression | ___ | ___ | ___ | ___ | 0.018 | ||
Yes | 44 (38.3%) | 11 | |||||
No | 71 (98.3%) | 33 | |||||